11. BioMerieux (EPA:BIM): +57.9%
Marcy-l’Étoile, France–based BioMerieux touts itself as a worldwide leader in in-vitro diagnostics, offering microbiological testing solutions for medical and industrial applications. Its R&D spend represented 12.9% of its overall revenue in its most recent fiscal, one of the largest percentages among medtech companies.
Last month, a new generation of the founding Mérieux family took over the helm of the company, with Alexandre Mérieux’s appointment as the company’s new chairman and CEO.
“I am determined to continue our family’s commitment to make bioMérieux a flagship company in the field of clinical and industrial diagnostics,” Mérieux said at the time. “Each day we see evidence of the importance of our work, and its impact on patients and consumers.”
DMo says
Was going to read this article but refuse to go through multiple clicks to see a list. Can you just give the list?
Chris Newmarker says
There’s a link on the opening slide where you can download a full spreadsheet of 100 companies and their stock performance. Hope that helps.